Zambon Group S.p.a.

Simes Societa Italiana Medicinali E Sintetici S.p.a.

Farmitalia Carlo Erba S.p.a.

Simes

Bio 3 Research S.r.l.

Zambon Group

Simes Societa Italiana Medicinali & Sintetici Spa

Simes Societa Italiana Medicinali E. Sintetici S.a.

Francesco Santangelo

Cesare Casagrande

Gabriele Pietro Norcini

Stefania Montanari

Claudio Semeraro

Giorgio Bertolini

Franco Pellacini

Paolo Cavalleri

Daniela Botta

Stefano Romagnano

Francesco Marchini

Gabriele Morazzoni

Mario Fantucci

Mauro Napoletano

Giancarlo Grancini

Roberto De Castiglione

Giuseppe Perseo

Cristina Fraire

Annibale Gazzaniga

Julio Alvarez-Builla

Gian Carlo Grancini

Enrico Albini

Giovanna Schioppacassi

Lorenzo Pradella

Silvano Piani

Fiorenzo Faoro

Napoletano Mauro

Felice Pocchiari

Jorge G Siro Herrero

Claudio Masotto

Jos&eacute; Luis Garcia Navaio

Luisa Calabi

Maria L Calabi

Girogio Bertolini

Luciano Soldati

The invention relates to a method and composition for treatment of oxidative stress resulting from hemodialysis treatment in patients suffering from chronic kidney failure or End-Stage Renal Disease by administration of cystine, cysteine or mixtures thereof.

Method for treating hemodialysis-related oxidative stress using cystine or cysteine

The present invention relates to methods of decreasing the effects of oxidative stress in patients undergoing hemodialysis by intravenously administering N-acetylcysteine or a pharmaceutically acceptable salt thereof to the patient.

Methods of decreasing the effects of oxidative stress using N-acetylcysteine

Compounds of formula (I) wherein B is alkylene, amino, CONH or a bond; Cy is optionally substituted phenyl or heteroaryl; R is H, phenyl or (C )alkyl optionally substituted; R is (C )alkyl or polyfluoro(C )-alkyl; R is (C )cycloalkyl optionally containing an oxygen atom and optionally substituted; and the N&rarr;O derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF&agr; inhibitors.

Phthalazine derivatives as phosphodiesterase 4 inhibitors

Compounds of formula (I) wherein R is an alkyl, aryl or arylalkyl group wherein the aryl is phenyl naphthyl or heterocycle; R and R , the same or different, are hydrogen atoms or alkyl groups; R is an aryl or arylalkyl group wherein the aryl is as above; R is a heterocycle optionally substituted with a heterocycle or phenyl, or it is a phenyl group substituted with a heterocycle (R is not imidazole or indole); X is a bond or &mdash;OCONH or &mdash;CONH&mdash; group, processes for their preparation and pharmaceutical compositions thereof, are described. The compounds of formula (I) are endowed with a dual ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular disease.

Phosphonic acid derivatives with metallopeptidase inhibitory activity

Hydroxymethyl derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene as cardiovascular agent

A process for the preparation of heteroaryl-zinc halides of the formula (II): Het&mdash;Zn&mdash;X, wherein Het is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen or sulphur; X is a chlorine, bromine or iodine atom; comprising metallation reaction of heteroarylhalide with metallic zinc optionally activated by washing with acids, is described. Compounds of the formula (II) are intermediates useful in the synthesis for the preparation of compounds endowed with pharmacological activity.

Process for the preparation of heteroaryl-zinc halides

Thiol derivatives with metallopeptidase (ACE/NEP) inhibitory activity

Naphthothiazolone derivatives active on the D.sub.3 dopaminergic receptor

Compounds of the formula: ##STR1## wherein the variables are as defined in the specification. These compounds are useful in the treatment of arterial hypertension and heart failure, of renal insufficiency, of peripheral arteriopathies and of cerebrovascular insufficiencies.

Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the

5-hydroxymethyl-2-aminotetralins as cardiovascular agents

Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described. The compounds of formula I are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Mercapto acyl aminoacid derivatives endowed with dual ACE-NEP inhibitory

Thiol derivatives with metallopeptidase inhibitory activity

Erythromycin A 9-0 oxime derivatives endowed with antibiotic activity

Phosphonyldipeptides useful in the treatment of cardiovascular diseases

Growing community of inventors

Milan, Italy

Francesco Santangelo